Meta-analysis of the studies of bleeding complications of platelets pathogen-reduced with the Intercept system

Vox Sanguinis

Volumn 102, Issue 4, 2012, Pages 302-316

  Vamvakas, E C ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Pathogen inactivation; Platelet components; Platelet transfusion

Indexed keywords

AMOTOSALEN;

ARTICLE; BLEEDING; DISEASE SEVERITY; HUMAN; INTERMETHOD COMPARISON; META ANALYSIS; OUTCOME ASSESSMENT; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK; RISK ASSESSMENT; SAFETY; STANDARD; STATISTICAL SIGNIFICANCE; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; ULTRAVIOLET A RADIATION;

BLOOD PLATELETS; DISEASE TRANSMISSION, INFECTIOUS; HEMORRHAGE; HUMANS; PLATELET TRANSFUSION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THROMBOCYTOPENIA;

EID: 84859863469     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/j.1423-0410.2011.01555.x     Document Type: Article

References (56)

1. Kerkhoffs JLH, van Putten WLJ, Novotny VMJ, et al. : Clinical effectiveness of leukoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. Br J Haematol 2010; 150:209-217
2. van Rhenen D, Gulliksson H, Cazenave JP, et al. : Transfusion of pooled buffy-coat platelet components prepared with a photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003; 101:2426-2433
3. McCullough J, Vesole DH, Benjamin RJ, et al. : Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT trial. Blood 2004; 104:1534-1541
4. Snyder E, McCullough J, Slichter SJ, et al. : Clinical safety of platelets photochemically-treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial. Transfusion 2005; 45:1864-1875
5. Janetzko K, Cazenave JP, Kluter H, et al. : Therapeutic efficacy and safety of photochemically-treated apheresis platelets processed with an optimized integrated set. Transfusion 2005; 45:1443-1452
6. Lozano M, Knutson F, Tardivel R, et al. : A multi-center study of the therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet-A pathogen inactivation stored for 6 or 7days prior to transfusion. Br J Haematol 2011; 153:393-401
7. Allain JP, Bianco C, Blajchman MA, et al. : Protecting the blood supply from emerging pathogens: the role of pathogen inactivation. Transfus Med Rev 2005; 19:110-126
8. McCullough J: Pathogen inactivation: a new paradigm for blood safety. Transfusion 2007; 47:2180-2184
9. Klein HG, Anderson D, Bernardi MJ, et al. : Pathogen inactivation: making decisions about new technologies. Report of a consensus conference. Transfusion 2007; 47:2338-2347
10. Vamvakas EC, Blajchman MA: Transfusion-related mortality: the on-going risks of allogeneic blood transfusion and the available strategies for their prevention. Blood 2009; 113:3406-3417
11. AuBuchon JP: Current status of pathogen inactivation methods. ISBT Sci Ser 2010; 5:125-133
12. Vamvakas EC: Meta-analysis of the randomized controlled trials of the hemostatic efficacy and capacity of pathogen-reduced platelets. Transfusion 2011; 51:1058-1071
13. Corash L, Sherman CD: Evaluation of platelet transfusion clinical trials. Br J Haematol 2011; 153:529-531
14. Kerkhoffs JLH: Evaluation of platelet transfusion clinical trials-Response to Corash and Sherman. Br J Haematol 2011; 153:531-532
15. Corash L: The hemostatic efficacy of platelet components prepared with pathogen inactivation. Transfusion 2011; 51:1355-1356
16. Lozano M, Knutson N, Tardivel R, et al. : A multicenter study of therapeutic efficacy and safety of platelet components prepared with pathogen inactivation (Intercept) stored for 6-7days prior to transfusion. Vox Sang 2010; 99(Suppl. 1):13
17. The Mirasol Clinical Evaluation Study Group: A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology. Transfusion 2011; 50:2363-2375
18. Vamvakas EC: The hemostatic efficacy of platelet components prepared with pathogen inactivation-In reply. Transfusion 2011; 51:1356-1359
19. Simonsen AC, Johansson PI, Conlan MG, et al. : Transfusion of 7-day-old amotosalen photochemically-treated buffy-coat platelets to patients with thrombocytopenia: a pilot study. Transfusion 2006; 46:424-433
20. Slichter SJ, Raife TJ, Davis K, et al. : Platelets photochemically treated with amotosalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia. Transfusion 2006; 46:731-740
21. Wollowitz S: Fundamentals of the psoralen-based Helinx technology for inactivation of infectious pathogens and leukocytes in platelets and plasma. Semin Hematol 2001; 38(Suppl 11): 4S-11S
22. Bruchmuller I, Janetzko K, Bugert P, et al. : Polymerase chain reaction inhibition assay documenting the amotosalen-based photochemical pathogen inactivation process of platelet concentrates. Transfusion 2005; 45:1464-1472
23. Kumar V, Lockerbie O, Keil SD, et al. : Riboflavin and UV-light based pathogen reduction: extent and consequence of DNA damage at the molecular level. Photochem Photobiol 2004; 80:15-21
24. Kerkhoffs JLH, Eikenboom JC, Schipperus MS, et al. : A multicenter randomized study of the efficacy of transfusions with platelets stored in platelet additive solution II versus plasma. Blood 2006; 108:3210-3215
25. Slichter SJ, Kaufman RM, Assmann SF, et al. : Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 2010; 362:600-613
26. Miller AB, Hoogsraten B, Staquet M, et al. : Reporting results of cancer treatment. Cancer 1981; 47:207-209
27. Webert KE, Cook RJ, Sigouin CS, et al. : The risk of bleeding in thrombocytopenic patients with acute myeloid leukemia. Haematologica 2006; 91:1530-1537
28. Heddle NM: Optimal timing and dosing of platelet transfusions. ISBT Sci Ser 2010; 5:88-94
29. Stanworth SJ, Dyer C, Casbard A, et al. : Feasibility and usefulness of self-assessment of bleeding in patients with hematologic malignancies, and the association between platelet count and bleeding. Vox Sang 2006; 91:63-69
30. Heddle NM, Cook RJ, Webert KE, et al. : Methodologic issues in the use of bleeding as an outcome in transfusion medicine studies. Transfusion 2003; 43:742-752
31. Rebulla P, Finazzi G, Marangoni F, et al. : The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. N Engl J Med 1997; 337:1870-1875
32. Heddle NM, Cook RJ, Timmouth A, et al. : A randomized controlled trial comparing standard and low-dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia. Blood 2009; 113:1564-1573
33. Stanworth SJ, Dyer C, Choo L, et al. : Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (Trial of Platelet Prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfus Med Rev 2010; 24:163-171
34. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177-188
35. Osselaer JC, Doyen C, Defoin L, et al. : Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use. Transfusion 2009; 49:1412-1422
36. Cazenave JP, Isola H, Waller C, et al. : Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3-year period. Transfusion 2011; 51:622-629
37. FDA/CBER. Study Designs (Phases 3 and 4) for Product Development of Human Platelets Using the Cerus INTERCEPT Blood System for Pathogen Inactivation. Meeting of the Blood Products Advisory Committee: November 16, 2009:158-345, Available at:
38. Friedman RC, Farh KK, Burge CB, et al. : Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 19:92-105
39. Fabian MR, Sonenberg N, Filipowicz W: Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem 2010; 79:351-379
40. Bruchova H, Yoon D, Agarwal AM, et al. : Regulated expression of microRNAs in normal and polycythemia vera erythropoiesis. Exp Hematol 2007; 35:1657-1667
41. Landry P, Plante I, Ouellet DL, et al. : Existence of a microRNA pathway in anucleate platelets. Nat Struct Mol Biol 2009; 16:961-966
42. Kondkar AA, Bray MS, Leal SM, et al. : VAMP8/endobrevin is overexpressed in hyperreactive human platelets: suggested role for platelet microRNA. J Thromb Haemost 2010; 8:369-378
43. Booyse FM, Rafelson ME Jr: Studies on human platelets. I. Synthesis of platelet protein in a cell-free system. Biochim Biophys Acta 1968; 166:689-697
44. Kieffer N, Guichard J, Farcet JP, et al. : Biosynthesis of major platelet proteins in human blood platelets. Eur J Biochem 1987; 164:189-195
45. Weyrich AS, Lindermann S, Tolley ND, et al. : Change in protein phenotype without a nucleus: translational control in platelets. Semin Thromb Hemost 2004; 30:491-498
46. Hong W, Konkar AA, Nagalla S, et al. : Transfection of human platelets with short interfering RNA. Clin Transl Sci 2011; 4:180-182
47. Nagalla S, Shaw C, Kong X, et al. : Platelet microRNA-mRNA co-expression profiles correlate with platelet reactivity. Blood 2011; 117:5189-5197
48. Edelstein LC, Bray PF: MicroRNAs in platelet production and activation. Blood 2011; 117:5289-5296
49. Osman A, Falker K: Characterization of human platelet microRNA by quantitative PCR coupled with an annotation network for predicted target genes. Platelets 2011; 22:433-441
50. Hitzler W, Vamvakas EC: Platelet microRNA profiles and the effect of pathogen reduction on platelet function. Clin Lab 2011; 57:451-454
51. Lozano M, Galan A, Mazzara R, et al. : Leukocyte-reduced buffy-coat derived platelet concentrates photochemically treated with amotosalen-HCI and ultraviolet A light stored up to 7days: assessment of hemostatic function under flow conditions. Transfusion 2007; 47:666-671
52. Osselaer JC, Cazenave JP, Lambermont M, et al. : An active haemovigilance programme characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment. Vox Sang 2008; 94:315-323
53. Osselaer JC, Messe N, Hervig T, et al. : A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment. Transfusion 2008; 48:1061-1071
54. Freedman B: Equipoise and the ethics of clinical research. N Engl J Med 1987; 317:141-145
55. Vamvakas E: Relative safety of pooled whole-blood-derived versus single-donor (apheresis) platelets in the United States: a systematic review of disparate risks. Transfusion 2009; 49:2743-2758
56. Miller FG, Joffee S: Equipoise and the dilemma of randomized clinical trials. N Engl J Med 2011; 364:476-480